Life Sciences

The Omica Cancer
Atlas

Multimodal oncology data from deeply admixed patient populations across Latin America.

The next generation of cancer therapies will be found at the edges of human variation.

Latin American populations carry combinations of ancestral variants rarely observed in existing research cohorts. Their tumor driver profiles, immune repertoires, and drug tolerance windows represent clinical evidence that datasets built on European and East Asian ancestry miss entirely.

Drivers Oncogenic drivers stratify by ancestry, concentrating distinct target classes in populations underrepresented in existing datasets.
Presentation Immunotherapy response is gated by HLA, the most polymorphic locus in the human genome. Admixed Latin American populations carry HLA haplotypes largely absent from current immunogenomics datasets.
Tolerance Therapeutic index is a germline trait whose bounds are defined at the population extremes, precisely the populations absent from registrational pharmacogenomics.

A multimodal atlas of human tumor biology.

Tissue to genome at cellular resolution. Built from an in-house biobank across deeply admixed populations in Latin America.

2B+ cells segmented
10M+ clinical entities extracted
200M+ pathology tiles processed
10K+ matched biosamples, admixed ancestry

Clinical

Structured longitudinal records. Treatment lines, response, and progression abstracted from unstructured notes at scale.

Tissue

Digitized, segmented, annotated. H&E and FFPE at cell-level resolution, captured at the point of care.

Outcomes

Survival and response by line of therapy, linked to molecular and morphologic features.

From discovery through evidence.

Discovery

Evidence

Discuss a data program